335 related articles for article (PubMed ID: 33957868)
21. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.
Zeidan AM; Giri S; DeVeaux M; Ballas SK; Duong VH
Ann Hematol; 2019 Feb; 98(2):339-350. PubMed ID: 30413901
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of transfusional iron overload].
Suzuki T
Rinsho Ketsueki; 2020; 61(9):1205-1211. PubMed ID: 33162517
[TBL] [Abstract][Full Text] [Related]
23. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Nolte F; Nückel H; Schmidt B; Geer T; Rubanov O; Hebart H; Jarisch A; Albrecht S; Johr C; Schumann C; Hofmann WK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
[TBL] [Abstract][Full Text] [Related]
24. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
25. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
[TBL] [Abstract][Full Text] [Related]
26. Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS.
Yang F; Cui X; Wang H; Zhang D; Luo S; Li Y; Dai Y; Yang D; Zhang X; Wang L; Zheng G; Zhang X
Cancer Lett; 2024 Feb; 583():216652. PubMed ID: 38242196
[TBL] [Abstract][Full Text] [Related]
27. Iron chelation therapy in myelodysplastic syndromes.
Fausel CA
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S10-4; quiz S16. PubMed ID: 20332500
[TBL] [Abstract][Full Text] [Related]
28. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
29. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
30. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
31. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
[TBL] [Abstract][Full Text] [Related]
32. [Iron overload and iron chelation therapy in transfusion-dependent patients].
Suzuki T
Nihon Rinsho; 2008 Mar; 66(3):563-8. PubMed ID: 18326327
[TBL] [Abstract][Full Text] [Related]
33. Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
Hua Y; Wang C; Jiang H; Wang Y; Liu C; Li L; Liu H; Shao Z; Fu R
Int J Hematol; 2017 Aug; 106(2):248-257. PubMed ID: 28405919
[TBL] [Abstract][Full Text] [Related]
34. Controversies surrounding iron chelation therapy for MDS.
Leitch HA
Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
[TBL] [Abstract][Full Text] [Related]
35. [Iron dysregulation and anemias].
Ikuta K
Rinsho Ketsueki; 2015 Oct; 56(10):1903-13. PubMed ID: 26458428
[TBL] [Abstract][Full Text] [Related]
36. The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Weber S; Parmon A; Kurrle N; Schnütgen F; Serve H
Front Immunol; 2020; 11():627662. PubMed ID: 33679722
[TBL] [Abstract][Full Text] [Related]
37. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Greenberg PL
J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
[TBL] [Abstract][Full Text] [Related]
38. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
Steensma DP; Gattermann N
Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
[TBL] [Abstract][Full Text] [Related]
39. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
Shander A; Sazama K
Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
[TBL] [Abstract][Full Text] [Related]
40. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Jabbour E; Kantarjian HM; Koller C; Taher A
Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]